TJ Biopharma completes nearly 600 million Yuan in financing to accelerate commercialization and globalization of innovative drugs

On September 30, 2025, TJ Biopharma ("TJ Bio"), a fully integrated biotech company focusing on discovery, development, manufacturing and commercialization of innovative biologics in the areas of autoimmune diseases, oncology and metabolic disorders, announced the successful completion of nearly RMB 600 million in Series C2 financing.

• A strategic collaboration with France's Sanofi on the Greater China rights for uliledlimab, with a total potential value of approximately RMB 1.7 billion;

• Successful submission of marketing applications for two products, including eftansomatropin alfa and felzartamab (for multiple myeloma indication);

• Initiation of an international multi-center Phase III clinical study in China for felzartamab treating IgA nephropathy and primary membranous nephropathy, in collaboration with U.S.-based Biogen;

• Designation of plonmarlimab as a Breakthrough Therapy by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA), with Phase III clinical trials already initiated.

• Felzartamab: A first-in-class, locally produced CD38 antibody with differentiated advantages. Its marketing application for the multiple myeloma indication has been accepted, and it shows substantial "pipeline-in-a-product" potential in autoimmune diseases. The international multi-center Phase III clinical trial for IgA nephropathy and membranous nephropathy, conducted in collaboration with Biogen, has been approved by the Center for Drug Evaluation (CDE) and is now initiating.

• Eftansomatropin Alfa: An innovative fully fused long-acting growth hormone. Its marketing authorization application has been accepted. By accelerating the localization of this product and leveraging the exceptional commercial capabilities of partner Jiangchuan Pharmaceutical, it is poised to capture a leading position in China's rapidly growing pediatric growth hormone market.

• Efmedaglutide Alfa (TJ103/TG103): A long-acting GLP-1 fusion protein developed in collaboration with CSPC Pharmaceutical Group, targeting the vast metabolic diseases market. It is planned to submit a marketing application in 2025.

• Uliledlimab (CD73): For first-line treatment of non-small cell lung cancer (NSCLC), its biomarker-driven clinical study has yielded excellent data. In September 2024, a strategic collaboration for Greater China rights with Sanofi was established, with a total potential value of approximately RMB 1.7 billion, and two first-line NSCLC clinical studies are progressing as planned.

• Plonmarlimab (GM-CSF): Targeting macrophage activation syndrome (MAS) and gouty arthritis. The MAS indication received Breakthrough Therapy Designation from China's NMPA in September 2024, and a Phase III clinical trial has been initiated. A Phase II/III clinical trial for gouty arthritis will also commence shortly.

• Givastomig (CLDN18.2x4-1BB Bispecific Antibody): A first-in-class bispecific antibody. When combined with PD-1 inhibitors and chemotherapy, it has demonstrated outstanding efficacy (83% objective response rate) and safety in first-line gastric cancer treatment, covering patients with low, medium, and high Claudin18.2 expression. TJ Biopharma holds the Greater China rights for this product and plans to initiate the next phase of clinical studies shortly.